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Background and purpose   One of the greatest problems of revision 
hip arthroplasty is dealing with lost bone stock. Good results have 
been obtained with impaction grafting of allograft bone. However, 
there have been problems of infection, reproducibility, antigenic-
ity, stability, availability of bone, and cost. Thus, alternatives to 
allograft have been sought. BoneSave is a biphasic porous ceramic 
specifically designed for use in impaction grafting. BoneSave is 
80% tricalcium phosphate and 20% hydroxyapatite. Previous in 
vitro and in vivo studies have yielded good results using mixtures 
of allograft and BoneSave, when compared with allograft alone. 
This study is the first reported human clinical trial of BoneSave 
in impaction grafting.
Methods   We performed a single-institution, multi-surgeon, 
prospective cohort study. 43 consecutive patients underwent revi-
sion  hip  arthroplasty  using  BoneSave  and  allograft  to  restore 
missing bone in the acetabulum. 9 patients had cemented ace-
tabular components implanted and 34 uncemented. 10 patients 
had cemented femoral components implanted and 1 had an unce-
mented femoral component. 32 patients did not have their femo-
ral component revised.
Results   No patients were lost to follow-up. At a mean follow-up 
of 24 (11–48) months, there were no re-revisions and there was no 
implant migration. 1 acetabular component had confluent lucent 
lines at the implant-graft interface. Complications were rare (1 
fracture, 2 dislocations). Patient satisfaction with the procedure 
was high. 
Interpretation      Short-term  results  indicate  that  impaction 
grafting of BoneSave and allograft is an effective method of deal-
ing with loss of bone stock at revision hip surgery.

Dealing with loss of bone stock is one of the greatest chal-
lenges  facing  the  revision  hip  surgeon.  Initial  attempts  to 
address  this  problem  yielded  poor  results. The  Exeter  and 
Nijmegen  groups  popularized  impaction  grafting  of  donor 
allograft  in  the  early  1990s  (Gie  et  al.  1993,  Slooff  et  al. 
1996). Their excellent clinical results have not always been 
reproduced elsewhere. Eldridge et al. (1997) reported an early 
massive subsidence of 12% of femoral stems. In addition, 
allografts in general have been associated with problems of 
infection (Huo et al. 1992, Simonds et al. 1992), antigenicity 
(Friedlander et al. 1984), availability (Galea et al. 1998), and 
cost (Tomford et al. 1981). 
For those reasons, a number of alternatives to allograft have 
been investigated. These include xenografts, various ceramics 
such as hydroxyapatite and other calcium-phosphates, coral, 
bamboo, and reinforced collagen matrices (Itokazu et al. 1996, 
Jensen et al. 1996, Li et al. 1997). Initial results have identi-
fied certain shortcomings with both xenografts and glass-iono-
mers. Xenografts osseointegrate less well than allograft, and, 
as with allograft, they show variability in particle size, particle 
morphology, and impaction properties. They are also associ-
ated with problems of infection (Charalambides et al. 2005) 
and antigenicity (Begley et al. 1995).
Glass-ionomers are non-compressible and, as they are non-
porous, they allow only peripheral osseointegration with no 
effective osseoconduction within the ceramic particles. Tsu-
ruga et al. (1997) and Kuhne et al. (1994) have shown that a 
pore size of approximately 300–400 μm in ceramics will allow 
optimal osseoconduction.
Hydroxyapatite and tricalcium phosphate ceramics have been 
shown to osseointegrate (Itokazu et al. 1996, Ransford et al. Acta Orthopaedica 2009; 80 (2): 150–154  151
1998), but concerns have been raised as to their ability to main-
tain their structural integrity under load (Hanft et al. 1995).
BoneSave is a biphasic porous ceramic bone graft substitute, 
specifically designed for use in impaction grafting in revision 
hip surgery. It is sintered at a high temperature in order to 
give it the requisite compressive strength to withstand the high 
compressive and shear forces associated with impaction graft-
ing. It has been tested extensively both in vitro (Blom et al. 
2002, Arts et al. 2005a, Van Haaren et al. 2005) and in vivo 
(Arts et al. 2005b, Blom et al. 2005a), but as yet there have 
been no published human clinical reports. Despite this, it is 
used throughout the world and in over 175 hospitals in the UK 
(Stryker, Newbury, UK, personal communication). 
We report the first human cohort study using BoneSave to 
restore missing bone at revision hip surgery.
Patients and methods
From 2003 through 2006, 43 hips in 43 patients at our hospital 
underwent revision total hip replacement for aseptic loosening 
with contained bony defects. All bony defects were grafted 
with a 50:50 volume mix of BoneSave (Table 1) and allograft 
from donor human femoral heads. 
The inclusion criterion was: all patients undergoing revision 
hip surgery for aseptic loosening with contained acetabular 
defects.
The  patients  were  a  consecutive  series  consisting  of  all 
patients  who  received  BoneSave  at  the Avon  Orthopaedic 
Centre, and the operating surgeons were the 4 authors (AB, 
GB, SEW and IL)
Patient demographics 
27 patients were female and 16 were male. Mean age was 71 
(42–90) years. The mean follow-up was 24 (11–48) months, 
with a total of 78 person years of observations. At 11 months, 
there were 43 patients at risk (i.e. still undergoing follow-up) 
and at 12 months there were 39 patients at risk. This fell to 18 
patients at 24 months, 6 patients at 36 months, and 2 patients 
at 48 months. 9 patients had had cemented acetabular com-
ponents and 34 had had uncemented acetabular components. 
11 patients had contained femoral defects that were grafted. 
10  patients  had  cemented  femoral  components  implanted 
and 1 had an uncemented femoral component implanted. The 
remaining 32 patients did not have the femoral component 
revised. 
The graft material was a 50:50 by volume mix of morsell-
ized allograft and BoneSave. Allograft was harvested from 
donor femoral heads and milled in a bone mill. Impaction 
grafting was performed as described by Bolder et al. (2007) 
using metal impactors and a hammer to compress graft into 
the acetabular defect. As the defects were contained, it was 
not necessary to use meshes or cages. Frozen sections and 
cultures were not taken to exclude infection. The uncemented 
cups were Pinnacle (De Puy International, Leeds, UK) or Pro-
cotyl (Wright, Arlington, TN) and the cemented were OGEE 
LPW (De Puy International). All patients were mobilized to 
full weight bearing within 48 h of surgery.
Patients were then followed up radiographically and clini-
cally at 3 months, 6 months, 1 year, and then annually. At 
latest review, they were sent a postal questionnaire consisting 
of the Oxford hip score (Dawson et al. 1996), the SF-12 (Ware 
et al. 1996) and the Satisfaction Scale for Joint Replacement 
Arthroplasty (Mahomed et al. 1997). The Oxford hip score 
is a 12-item patient-reported outcome measure assessing hip 
pain and functional limitations on a scale of 12–60 (low-high 
disability). The SF-12 is a general health questionnaire, which 
produces a Physical Component score and Mental Compo-
nent score scale from 0 to 100 (representing poor to excel-
lent  health).  The  Satisfaction  Scale  for  Joint  Replacement 
Arthroplasty  consists  of  4  questions  asking  respondents  to 
rate their satisfaction with hip replacement in terms of pain 
relief, ability to perform activities of daily living (ADLs), abil-
ity to partake in leisure activities, and overall satisfaction. A 
total satisfaction score can then be calculated on a scale of 0–
100 (ranging from full dissatisfaction to full dissatisfaction). 
In addition, a question was included asking patients if they 
would undergo the operation again, based on their experience 
of the hip replacement. 
Results
No new technical problems were identified with the impac-
tion  process. The  operating  surgeons  were  all  experienced 
with the impaction technique using allograft, and found that 
impaction of the mixture to be no more technically demand-
ing. There were no revisions and no impending revisions of 
the  construct  at  11–48  months.  There  were  no  infections. 
There were 2 single dislocations, one on day 2 and the other 6 
weeks postoperatively. Both dislocations were reduced closed. 
There was 1 femoral fracture distal to the tip of the prosthesis, 
which occurred 4 months after surgery and was fixed with a 
strut graft and femoral plate. The patient made an uneventful 
recovery. 
No  patients  were  lost  to  follow-up.  38  of  43  question-
naires were returned; 4 patients died and 1 patient suffered 
from advanced dementia, and was thus unable to complete the 
Table 1. Characteristics of BoneSave
Composition  80% tricalcium phosphate
  20% hydroxyapatite
Sintering temperature  > 1,200°C (to achieve optimum hardness)
Crystallinity  High (> 80%)
Porosity  50% by volume
  Pore size 300–500 μm
Granule size  2–8 mm152  Acta Orthopaedica 2009; 80 (2): 150–154
questionnaire. Taking missing data into account, Oxford hip 
scores were available from 32 patients, SF-12 scores from 35 
patients, satisfaction scores from 35 patients, and the answer 
on repeating the operation from 34 patients.
The mean overall satisfaction score was 75 (range 17–100; 
SD 27; 95% CI: 66–84) (Table 2).
The mean Oxford hip score was 26.9 (range 13–55; SD 11; 
95% CI: 23–31) (Table 3). 
The mean Mental Component score was 48 (range 20–66; 
SD 11; 95% CI: 31–39) and the mean Physical Component 
score was 36 (range 21–57; SD 11; 95% CI: 44–52).
27 patients stated that they would go through the operation 
again, 4 stated they would not have the operation again, and 3 
patients were unsure.
Radiographic results
All radiographs were available for assessment. No radiographs 
showed any signs of component migration, as measured on 
plain radiographs referencing from the tear drop and the tran-
sischial line. BoneSave granules were not visible in the soft 
tissues on postoperative radiographs, but were clearly visible 
in the impaction grafting construct. There were no incidences 
of heterotopic ossification or accelerated polyethylene wear, as 
assessed by measuring femoral head concentricity. 1 radiograph 
showed confluent lucent lines of greater than 2 mm thickness 
Table 2. Satisfaction scale
  Very  Somewhat  Somewhat  Very 
Satisfaction  satisfied   satisfied   dissatisfied  dissatisfied
overall   24  7  3  1
with pain relief  22  8  3  2
with ability to 
   perform  ADLs  14  13  3  5
with leisure activities  12  13  7  3
Table 3. Oxford hip score
Oxford hip score  12–20  21–30  31–40  41–50  51–60
No. of patients  10  11  6  4  1
Figure 2C. 3 years postoperatively. The 
acetabular component remains well fixed 
with integration of BoneSave graft.
Figure 2B. Postoperatively. Well-fixed acetab-
ular component with visible BoneSave gran-
ules impacted.
Figure 2A. Preoperatively. Loose acetabular com-
ponent and migration, leading to dislocation.
Figure 1B. 3 years postoperatively, showing stable radiolucency with 
excellent clinical results.
Figure 1A. 1 year postoperatively. Demonstrates 2-mm-thick confluent 
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around the acetabular component. At 3-year follow-up, this 
patient had an excellent clinical result and was pain-free with a 
normal gait (see Figures 1A and 1B). Case 2 (illustrated in Fig-
ures 2A, 2B, and 2C) was typical of our series. Of the patients 
who received an uncemented component, 10 of 34 had lucent 
lines at the component-graft interface, which were all less than 
2 mm in thickness at latest review. 4 of these were in DeLee 
and Charnley zones 1, 2, and 3, 4 were in zone 3 only, and 2 
were in zones 1 and 2. Of the patients who received a cemented 
component, 1 of 9 had a lucent line at the cement-graft inter-
face, which was less than 2 mm in thickness at latest review 
and was present in DeLee and Charnley zones 1 and 2. 
Discussion
Our results are short-term and must be interpreted with cau-
tion. It remains to be seen whether they may reflect long-term 
success. A number of centers have reported excellent results 
with impaction grafting of all allograft in the acetabulum, in 
the medium to long term (Schreurs et al. 2004, Deakin and 
Bannister 2007, Somford et al. 2008). Not all results of impac-
tion grafting of the acetabulum with allograft have been favor-
able, however, and there may be bulk limitations (Van Haaren 
et al. 2007). 
The bone defects in our patients are simply described as 
being  contained  rather  than  being  classified  according  to 
one of the commonly used classification systems such as the 
Paprosky (Paprosky et al. 1994) or AAOS (D’Antonio 1992). 
Previously published work from our institution has demon-
strated that these classification systems lack inter- and intrao-
bserver reliability, and do not correlate very well with intraop-
erative findings (Gozzard et al. 2003). 
Our study has a number of shortcomings, in that it was not 
a randomized controlled trial, in that the follow-up was short, 
and that both cemented and uncemented acetabular compo-
nents were used. Furthermore, the method of assessing com-
ponent migration was not very sensitive compared to methods 
such as RSA; thus, small migrations may have been missed. 
The results do, however, demonstrate that the concept works 
in the short term and they show the need for a randomized, 
controlled trial comparing impaction grafting with allograft 
alone with mixtures of allograft and bone-graft substitutes. 
The particular biphasic porous ceramic bone graft substi-
tute we used has been shown to be both more stable and more 
reproducible than allograft in mechanical engineering testing 
with both femoral (Blom et al. 2002) and acetabular models 
(Arts et al. 2005a). Furthermore, ovine and caprine studies 
have shown impaction grafting with BoneSave to be as least 
as good as allograft in the clinical setting with regard to func-
tion, radiographic analysis, and new bone formation (Arts et 
al. 2005b, Blom et al. 2005a). As the ceramic was mixed with 
allograft, it would not completely eliminate the risks of antige-
nicity and infection. However, using a ceramic bone graft sub-
stitute in this way markedly reduces the amount of allograft 
bone implanted and thereby reduces the risk of immune reac-
tion and infection.
We found none of the adverse reactions associated with other 
types of bone graft substitutes. Previous studies with Surgi-
bone (a bovine-derived bone graft substitute) have shown an 
extremely high revision rate for presumed infection (Chara-
lambides et al. 2005). In contrast, there were no infections in 
this study. 
BoneSave has a number of advantages over allograft, in that 
it is reproducible, provides a stable construct (with no implant 
migration), osseointegrates (Blom et al. 2005a), and has no 
intrinsic risk of infection and antigenicity. In addition, it has a 
pore size that has been demonstrated to be optimal for osseo-
conduction  (Tsuruga  et  al.  1997).  Because  BoneSave  was 
mixed with allograft, it reduced the amount of allograft needed 
and thereby reduced the risk of infection and antigenicity. 
We found no untoward side effects, such as unexpected het-
erotopic ossification. The complication rates were low com-
pared to other studies of revision hip surgery (Eldridge et al. 
1997, Blom et al. 2003, 2005b).
The patients were satisfied with the clinical outcome, partic-
ularly with regard to pain relief, and most of the patients stated 
that they would have undergone the same procedure again. 
The high percentage of fine lucent lines evident at the latest 
radiographic  review  may  be  a  predictor  of  future  implant 
migration, and highlights the need for long-term review. How-
ever, with impaction grafting, when catastrophic failure has 
occurred (be it because of infection or implant migration), it 
has usually occurred within 1 year of surgery (Charalambides 
et al. 2005, Eldridge et al. 1997). Despite the fact that Bone-
Save appears to be safe according to our evaluation, longer 
follow-up  is  necessary  before  this  material  can  be  recom-
mended for general use.
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